(Reuters) - Boston Scientific Corp on Tuesday said it reached its first settlement agreement to resolve a portion of the legal claims it faces involving its transvaginal mesh product to treat urinary incontinence.
The medical device maker, in a regulatory filing, said it expects to pay about $119 million to resolve 2,970 cases.
The Marlborough, Massachusetts-based company said it faces more than 25,000 mesh claims in total in U.S. federal and state courts. In November, it lost its first two federal trials, in West Virginia and Miami.
Help employers find you! Check out all the jobs and post your resume.
